TILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Instil Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$5.79−0.12 (-2.03%)

Close on Oct 19, 2026

Market cap: $39.27M
P/E (TTM): –
Dividend yield: –

Instil Bio, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31	Q4 2019 2019-12-31
Cash & Equivalents	5.54	5.02	6.64	5.80	7.84	16	11	6.66	6.78	5.48	11	10	23	28	44	42	43	62	38	21	567	610	242	171	182	5.61	8.90
Short-Term Investments	–	–	–	–	–	–	–	–	–	–	141	174	180	196	217	262	312	318	417	495	–	–	0	–	–	–	–
Cash & Short-Term Investments	5.54	5.02	6.64	5.80	7.84	16	11	6.66	6.78	5.48	152	184	203	224	261	304	355	380	455	516	567	610	242	171	182	5.61	8.90
Prepaid Expenses & Other	1.67	1.51	3.04	4.22	3.32	2.56	9.33	12	6.32	6.33	8.90	11	12	9.31	8.46	10	13	11	9.92	7.73	7.74	4.12	4.42	–	–	–	–
Other Current Assets	0.08	0.14	0.15	0.16	0.15	0.19	0.96	1.96	–	–	2.60	–	–	–	–	–	–	–	–	0	0	0.07	0.07	–	–	–	–
Total Current Assets	72	188	191	196	207	219	124	133	155	161	161	196	221	240	269	314	368	391	464	523	574	614	246	–	–	–	–
Property, Plant & Equipment	112	0.11	0.13	0.14	0.15	0.16	129	130	133	134	139	139	181	180	197	185	167	141	122	104	79	63	55	–	–	–	–
Gross Property, Plant & Equipment	112	–	0.51	0.51	0.51	0.51	134	134	138	138	146	146	187	185	205	191	172	145	125	106	80	64	56	–	–	–	–
Accumulated Depreciation	-0.64	-0.39	-0.38	-0.37	-0.36	-0.35	-4.78	-4.04	-5.34	-4.36	-7.56	-6.29	-5.51	-5.26	-8.48	-6.36	-4.62	-3.73	-2.98	-2.09	-1.35	-0.71	-0.31	–	–	–	–
Construction in Progress	–	–	–	–	–	–	–	–	–	–	–	–	–	–	104	–	–	–	67	44	23	–	6.30	–	–	–	–
Long-Term Investments	–	–	–	3.44	12	7.19	0	2.56	3.97	7.67	23	–	–	–	0	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	2.15	0.06	0.24	0.42	0.59	0.76	0.93	1.10	1.71	1.94	2.39	2.67	3.16	3.41	12	13	14	14	0	–	–	–	–	–	–	–	–
Goodwill	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	5.72	5.72	5.72	5.72	5.72	5.72	5.72	5.72	–	–	5.72	–
Other Long-Term Assets	3.91	3.99	4.07	4.15	11	10	4.49	6.18	0.58	1.77	0.64	2.54	3.10	3.63	3.41	5.01	4.25	3.08	8.14	4.79	3.81	3.70	1.71	–	–	–	–
Total Assets	198	200	204	212	231	237	264	273	294	306	326	340	408	427	482	533	569	565	610	647	673	696	319	–	–	–	–
Accounts Payable	0.80	0.79	0.78	0.93	0.52	0.29	0.66	1.20	1.22	1.23	1.21	1.65	2.16	1.35	2.36	5.33	5.79	7.71	5.57	5.25	5.23	3.73	3.50	–	–	–	–
Current Portion of Leases	0.39	0.19	0.37	0.31	0.46	2.39	1.68	1.76	1.67	1.68	1.75	1.80	1.88	2.10	2.38	2.28	1.98	1.91	0	–	–	–	–	–	–	–	–
Other Current Liabilities	–	–	–	–	–	–	0	0.11	0.14	0.15	0.19	0.32	0.34	0.54	0.59	0.93	0.89	0.64	0.39	0.23	0.19	0.17	0.28	–	–	–	–
Total Current Liabilities	3.31	4.72	4.84	5.70	14	7.23	7.90	10	10	11	11	13	18	27	33	42	43	37	41	32	24	17	13	–	–	–	–
Long-Term Leases	1.84	–	0	0	0.01	0.05	1.02	1.41	2.02	2.45	2.88	3.29	3.70	4.18	5.17	5.63	6.02	6.53	0	–	–	–	–	–	–	–	–
Operating Lease Liabilities	2.23	0.19	0.37	0.31	0.46	2.44	2.70	3.17	3.69	4.13	4.63	5.08	5.58	6.29	7.55	7.91	8.00	8.44	0	–	–	–	–	–	–	–	–
Deferred Tax Liabilities	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0.56	1.09	1.95	2.43	1.48	2.11	2.27	2.47	–	–	–	–
Other Long-Term Liabilities	0	0.01	0.01	0.09	0.09	0.09	0.08	0.01	0.01	0.04	0.08	0.12	0.16	0.20	0.33	0.38	0.35	0.02	0.02	1.54	1.11	0.31	0	–	–	–	–
Total Liabilities	90	90	90	91	99	93	94	96	99	100	100	106	112	116	119	122	110	56	55	46	37	31	27	–	–	–	–
Preferred Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	–	–	–	0	–	–	–	–	–	–	–	–
Common Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	–	–	–	–
Additional Paid-In Capital	843	842	841	839	837	829	825	820	816	812	807	803	798	794	789	782	774	765	757	748	739	733	5.61	–	–	–	–
Retained Earnings	-735	-731	-726	-718	-705	-683	-655	-643	-620	-605	-581	-568	-501	-482	-425	-371	-315	-256	-202	-146	-103	-68	-45	–	–	–	–
Comprehensive Income & Other	-0.59	-0.53	-0.58	-0.61	-0.81	-0.45	-0.23	-0.52	-0.63	-0.56	-0.35	-0.53	-0.80	-0.41	-0.49	-0.34	-0.56	-0.44	-0.09	-0.10	-0.21	-0.25	-0.28	–	–	–	–
Shareholders' Equity	107	111	114	120	132	145	169	176	195	206	226	234	297	311	364	411	458	509	555	601	635	665	-40	-23	-16	-7.71	-6.89
Total Equity	107	111	114	120	132	145	169	176	195	206	226	234	297	311	364	411	458	509	555	601	635	665	-40	-23	-16	-7.71	-6.89
Total Liabilities & Equity	198	200	204	212	231	237	264	273	294	306	326	340	408	427	482	533	569	565	610	647	673	696	319	–	–	–	–
Shares Outstanding(shares)	6.78	6.78	6.78	6.78	6.75	6.56	6.53	6.53	6.50	6.50	6.50	6.50	6.50	6.50	6.50	6.49	6.48	6.46	6.45	6.44	6.44	6.44	1.03	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -50.4%

Financial strength

Current ratio: 21.67
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 167.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.37
Dividend yield: –